The Pseudomonas aeruginosa product pyochelin interferes with Trypanosoma cruzi infection and multiplication in vitro
| Autor: | David A. Stevens, Laura C Miller Conrad, Terrence-Thang H Nguyen, Gabriele Sass |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Chagas disease Trypanosoma cruzi 030106 microbiology 030231 tropical medicine Virulence medicine.disease_cause Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Phenols parasitic diseases Chlorocebus aethiops medicine Animals Chagas Disease Vero Cells Pyoverdine biology Pseudomonas aeruginosa Public Health Environmental and Occupational Health General Medicine biology.organism_classification medicine.disease Quorum sensing Thiazoles Infectious Diseases chemistry Benznidazole Vero cell Parasitology Original Article medicine.drug |
| Zdroj: | Trans R Soc Trop Med Hyg |
| ISSN: | 1878-3503 |
| Popis: | Background Bacteria are sources of numerous molecules used in treatment of infectious diseases. We investigated effects of molecules produced by 26 Pseudomonas aeruginosa strains against infection of mammalian cell cultures with Trypanosoma cruzi, the aetiological agent of Chagas disease. Methods Vero cells were infected with T. cruzi in the presence of wild-type P. aeruginosa supernatants or supernatants of mutants with defects in the production of various virulence, quorum sensing and iron acquisition factors. Quantification of T. cruzi infection (percentage of infected cells) and multiplication (number of amastigotes per infected cell) was performed and cell viability was determined. Results Wild-type P. aeruginosa products negatively affected T. cruzi infection and multiplication in a dose-dependent manner, without evident toxicity for mammalian cells. PvdD/pchE mutation (loss of the P. aeruginosa siderophores pyoverdine and pyochelin) had the greatest impact on anti–T. cruzi activity. Negative effects on T. cruzi infection by pure pyochelin, but not pyoverdine, or other P. aeruginosa exoproducts studied, were quantitatively similar to the effects of benznidazole, the current standard therapy against T. cruzi. Conclusions The P. aeruginosa product pyochelin showed promising activity against T. cruzi and might become a new lead molecule for therapy development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|